Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial için istatistikler
Toplam ziyaret
| views | |
|---|---|
| Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial | 0 |
Aylık toplam ziyaret
| views | |
|---|---|
| Ocak 2024 | 0 |
| Şubat 2024 | 0 |
| Mart 2024 | 0 |
| Nisan 2024 | 0 |
| Mayıs 2024 | 0 |
| Haziran 2024 | 0 |
| Temmuz 2024 | 0 |
